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Drug dosage adjustment for patients with acute or chronic
kidney disease is an accepted standard of practice. The
challenge is how to accurately estimate a patient’s kidney
function in both acute and chronic kidney disease and
determine the influence of renal replacement therapies on
drug disposition. Kidney Disease: Improving Global
Outcomes (KDIGO) held a conference to investigate these
issues and propose recommendations for practitioners,
researchers, and those involved in the drug development and
regulatory arenas. The conference attendees discussed the
major challenges facing drug dosage adjustment for patients
with kidney disease. In particular, although glomerular
filtration rate is the metric used to guide dose adjustment,
kidney disease does affect nonrenal clearances, and this is
not adequately considered in most pharmacokinetic studies.
There are also inadequate studies in patients receiving all
forms of renal replacement therapy and in the pediatric
population. The conference generated 37 recommendations
for clinical practice, 32 recommendations for future research
directions, and 24 recommendations for regulatory agencies
(US Food and Drug Administration and European Medicines
Agency) to enhance the quality of pharmacokinetic and
pharmacodynamic information available to clinicians.
The KDIGO Conference highlighted the gaps and focused
on crafting paths to the future that will stimulate research
and improve the global outcomes of patients with acute and
chronic kidney disease.
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In May 2010, Kidney Disease: Improving Global Outcomes
(KDIGO) convened a Controversies Conference titled ‘Drug
Prescribing in Kidney Disease: Initiative for Improved
Dosing’. The conference, attended by 50 international experts,
including representatives from the US Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA), was designed to explore our understanding of drug
disposition in patients with acute kidney injury (AKI) and
chronic kidney disease (CKD), and to propose recommenda-
tions for the optimization of pharmacotherapy in the most
common clinical practice settings. The plenary session
presentations were followed by breakout group discussions
to address four specific issues that the conference planning
committee considered to be of central importance: (1) effects
of impaired kidney function on drug disposition and
response, (2) patient assessment for drug dosing, (3)
calculating drug doses for patients with AKI and CKD, and
(4) drug removal by intermittent and continuous renal
replacement therapies. The breakout group deliberations
were reported to the entire group and a consensus-building
process led to the clinical practice, research, and regulatory
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recommendations from the conference attendees, which is
the substance of this report. The conference agenda, selected
presentations, and abstracts of the meeting are available on
the KDIGO website (http://www.kdigo.org/meetings_events/
drug_Prescribing_in_KD-Initiative_for_Improved_Dosing.
php).
AKI and CKD can affect multiple organ systems and these
physiological changes have been associated with profound
alterations in the pharmacokinetics (PK) and the pharma-
codynamics (PD) of many drugs.1,2 Clinicians must assess
kidney function and consider how the kidney function-
associated changes in the disposition of drugs and their active
or toxic metabolites will impact the drug therapy needs of
individual patients.
The number of patients with AKI and CKD has increased
dramatically in the past 10 years.3,4 Advances in the treatment
of disease in general have permitted patients to live
longer and many of them develop decreased kidney function
over time. Indeed, kidney function decreases with age,
and older patients constitute the most rapidly expanding
patient group with CKD. The introduction of many
novel renal replacement therapies (RRTs) for treating AKI
and CKD mandate an understanding of their influence on
drug disposition and response. New hemodialysis (HD)
membranes and devices, intermittent, automated and
continuous peritoneal dialysis, and the development of
continuous RRTs necessitate evaluations and in some cases
reevaluations of drug transport across biological and artificial
membranes.
Pharmacotherapy is now widely utilized to manage
chronic conditions by primary care providers, and intensi-
vists are frequently faced with the need to individualize the
acute care medication needs while not upsetting the patient’s
delicate therapeutic balance. CKD patients have poorer
health outcomes than patients with normal renal function
and the nonoptimization of drug therapy may be one of the
contributing factors that could be addressed if more data
were available and emphasis was focused on its incorporation
into patient care plans.
THE CONTROVERSY
The pharmacokinetic era that began in the 1960s provided
many methods to quantify drug concentrations and tools to
characterize the influence of multiple factors including
kidney function on the disposition of drugs.5,6 In subsequent
years the pharmaceutical industry began to investigate the
relationship of kidney function and the PK as well as the PD
of the drugs they had in development. There was no
regulatory agency guidance during the 1970s to early 1990s
that provided a framework for when investigations should be
conducted and with what degree of rigor. Thus, much of the
information on the PK/PD of drugs in patients with renal
insufficiency was the result of clinician-initiated postmarket-
ing studies. These studies often employed small sample sizes
and resulted in the publication of frequently inconsistent or
in some cases even conflicting recommendations regarding
the need for drug dosage regimen adjustment. Comprehen-
sive evaluations of clinical PK and PD of drugs and the
resultant drug dosage regimen adjustment recommendations
for CKD patients has been the topic of hundreds of articles in
the past two decades and has become a standard feature in
almost all clinical pharmacology and therapeutics textbooks.
This wealth of data and expert opinion has fueled controversy
regarding almost every step in the process of drug therapy
individualization. The critical questions range from: What
patient assessment considerations should be factored into the
decision-making process? What is the most accurate and
reliable index of ‘kidney function’ for drug dosing? What are
the determinates of the desired therapeutic end points that
guide therapy, the significance of risk associated with the
accumulation of excessive drug and/or metabolite concentra-
tions, and the degree of impact of AKI or CKD on the PK or
PD of a drug? How to make pharmaceutical company-
derived drug PK and PD readily available to clinicians? What
is the predictive performance of the various methodologies to
calculate the desired dosage regimen? What are the essential
criteria that need to be met to reliably quantify the influence
of RRTs on a drug PK and PD, which mathematical methods
should be used to individualize drug therapy for those
receiving RRTs, and finally what educational efforts should be
developed to enhance drug prescribing for patients with AKI
and CKD?
ASSESSMENT OF KIDNEY FUNCTION
The standard measure of kidney function for decades has
been the glomerular filtration rate (GFR).7 The measurement
of GFR can be accomplished using many exogenous
substances. Urinary clearance of inulin, which is the gold
standard, is rarely performed except for research purposes
because of the limited availability of the substance and the
labor intensity of the procedure and the assay.8 Modifications
to this procedure include the use of other exogenous agents
such as iothalamate, iohexol, and (99 m)Tc/c-diethylenetri-
amine pentaacetic acid, and plasma clearance to replace the
need for urine collections. These are all more commonly
available and utilized, but have limitations.9 For example,
some of the markers are not completely eliminated by GFR
but are secreted by the tubules. Calculation of plasma
clearance requires extrapolation of the area under the curve
(AUC), which is often unreliable in those with the greatest
degree of kidney function impairment or those with extensive
edema, and even with these markers, the procedures are
cumbersome and subject to error unless done under careful
controlled conditions.10 The determination of GFR based on
the administration of exogenous substances is not practical
for routine individual drug dose calculations as they are not
timely and not uniformly available.
The determination of GFR utilizing an endogenous
substance has therefore been based on the urinary clearance
of creatinine (CLcr) derived from a 24 h urine collection.
7,11,12
This method is of limited clinical value because of frequent
urine collection errors (even when relatively short urine
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collection durations of 2–12 h are utilized), analytical inter-
ference with the serum or urine creatinine assay as the result of
concomitant diseases and drug therapies, and the associated
delay in the reporting of the results.8 Therefore, GFR is
predominantly estimated in clinical practice from the measure-
ment of endogenous substances such as serum creatinine (Scr)
and then combined with patient factors to estimate the GFR
using estimating equations.13–19 The advantage of this method
is that the results are available for routine clinical practice, and
that for the majority of people, estimated GFR provides an
unbiased assessment of measured GFR.17 Estimating equations
are on average more accurate than measured creatinine
clearance, given the errors in urine collection (Table 1).17
There are limitations to Scr. In particular, because Scr is
generated from muscle mass and diet, individuals at the
extremes of these factors (for example, amputee or conversely
body builders, or those on a vegan diet) will have
substantially different values of creatinine than expected,
and therefore the estimated GFR will be higher or lower than
the true GFR for an individual patient and imprecision of the
equation overall.20 This limitation of Scr is regardless of
which equation is used to estimate GFR, and cannot be
overcome by an adjustment of the equation.9
Another limitation of Scr is the variability in Scr assays.
The variation in the assays led to differences in reported Scr
values among laboratories as well as within laboratories over
time, even when the same methods are used.21 This variation
leads to differences in estimated GFR values when these
different assays are used. In 2005, the National Institute of
Standards and Technologies released materials that are
traceable to the certified reference materials for creatinine
whose value was assigned using isotope dilution mass
spectroscopy (IDMS).22,23 It is now estimated that the
majority of laboratories currently report creatinine values
traceable to this reference method. It is not possible to
determine the precise relationship between IDMS-standar-
dized Scr values and prior values because of the substantial
variability even within the same method in their creatinine
results. For example, creatinine measurements by the various
Jaffe methods yield Scr values that are 5–10% higher on
average than determinations by the IDMS technique.
Although some have proposed a singular ‘correction’ value
approach when using equations that were derived from
creatinine measured by the Jaffe method (SCr
(IDMS)¼ 0.92 SCr (Jaffe)), this is not a valid approach
given the wide variability among and within methods
described above. Recently, some have proposed and devel-
oped a methodology to convert IDMS-traceable Scr values
into non-IDMS-calibrated Scr values for application in CLcr
calculations to determine drug dosage adjustments.24 This
institution-specific methodology avoids the inappropriate
‘generalization’ of one correction factor to many patient care
settings but it may not be feasible for most clinicians to utilize
in their practice. The use of IDMS creatinine assays will likely
lead to less variation in kidney function estimates and
theoretically more consistent drug dosing recommendations
across institutions and clinical settings. However, the variation
in the creatinine assays before the availability of standardized
creatinine assays does effect the relationships from PK/PD
drug studies of the past, and therefore interpretation of
product label drug dosing recommendations in the current
era.25 Estimated GFR based on current creatinine assays are
likely to yield different drug dosage recommendations from
those intended by the original study even if the same
estimating equation is used because of this change in
analytical methodology. It is not possible or practical to
repeat all of the PK studies with standardized creatinine, and
therefore as discussed in the section below ‘drug dosing
consideration for patients with CKD’, it is still reasonable to
use drug dosing adjustments in the product labeling.
Historically, the most frequently clinically used equation
to estimate GFR has been the Cockcroft and Gault (CG)
equation13 (see Table 1). This equation provides an estimate
of measured CLcr and has been widely used as an estimate of
GFR as well, despite the fact that creatinine also undergoes
tubular secretion. The CG equation is reported in units
not adjusted for body surface area, which is appropriate
for drug dosage adjustment. The CG equation has been
shown to overestimate GFR with the use of standardized
creatinine assays.26 Many have considered that an advantage
of the CG equation for individual drug dose adjustment is
that the body weight is considered; however, this has not been
validated. Similarly, many modifications to the CG equation
have been proposed, such as use of lean body mass when
estimating GFR in obese patients, but this too has not been
validated.27
Table 1 |Mathematical approaches to estimate GFR that have been proposed to guide drug dosage adjustment
Equations Units Reference
Cockcroft and Gault
CLcr=(140age (years)weight (kg) 0.85 [female])/(Scr (mg/dl) 72)
ml/min 13
MDRD (four-variable) Study equation
GFR=186.3  Scr1.154 Age0.2031.212 [black]  0.742 [female]
ml/min per 1.73m2 19
MDRD (four-variable) Study equation for IDMS serum creatinine
GFR=175.6  Scr1.154 Age0.2031.212 [black]  0.742 [female]
ml/min per 1.73m2 19
CKD-EPIa
GFRa=141 min (Scr/k,1)a max (Scr/k,1)1.209  0.993Age  1.159 [black]  1.018 [female]
ml/min per 1.73m2 17
Abbreviations: CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; CLcr, creatinine clearance; GFR, glomerular filtration rate; IDMS, isotope dilution mass
spectroscopy; MDRD, Modification of Diet in Renal Disease.
aHere, k is 0.7 for females and 0.9 for males, a is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k
or 1 and age is measured in years.
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The Modification of Diet in Renal Disease (MDRD) Study
equation was developed from an extensive sample of patients
with CKD, all of whom had a measured GFR using urinary
clearance of 125I iothalamate of o90 ml/min per 1.73 m2
(ref. 28). This equation is now widely reported by clinical
laboratories around the world whenever Scr is reported.
29 The
MDRD Study equation has been shown to overestimate
measured GFR in those with values 460 ml/min per 1.73 m2,
and hence specific values are only reported for values
o60 ml/min per 1.73 m2 (ref. 29). The CKD-Epidemiology
Collaboration (CKD-EPI) equation was recently developed
specifically to overcome this limitation. It is more accurate
than the MDRD Study equation, particularly at higher levels
of GFR.17,30 The CKD-EPI equation is now reported by Quest
and LabCorp, the two largest laboratory service providers in
the United States, and with it the GFR estimates are now
reported throughout the GFR range.
Hence, which one of the many GFR estimation equations
should be used for assessment of an individual patient’s GFR
as the guide to the degree of adjustment of their drug dosage
regimens? The pros and cons of the various GFR-estimating
equations have been extensively reviewed and there is no
compelling evidence of the superiority of any given method
for drug dosing in all patient populations or clinical
situations.27,31–35 Most of these studies have all compared
the equations with each other in hypothetical simulations
and not with actual drug clearance.36–44 The National Kidney
Disease Education Program (NDKEP) in the United States
recommends that the GFR estimated from the MDRD Study
or CLcr estimates from the CG equation for adults or the
Schwartz equation for children can be used for drug dosing.22
For very large or very small people, they recommend
adjustment of the estimated GFR (eGFR) from the MDRD
Study equation to account for patient’s body surface area
(BSA) ((eGFRIND ¼ eGFRMDRD  (BSA per 1.73 m2)) to yield
a eGFRIND in units of ml/min.
25,34
It is most important that clinicians have ready access to at
least one GFR estimate for all of their patients. Currently, the
CKD-EPI method is the most accurate method for estimation
of GFR,17 and it appears to be emerging as the method of
choice for the staging of CKD. Although documentation of
its utility for drug dosing is limited,45 it is likely to be similar
to the MDRD Study equation given the similar performance
at lower levels of GFR, where dose adjustment is frequent.
Clinicians should use the method that provides the
most accurate assessment of GFR. In particular, this is of
utmost importance for those drugs with a narrow therapeutic
index for which dosing individualization is required. In
those clinical situations where any creatinine-based
estimation equation is not likely to provide a good estimate
of GFR, measured creatinine clearance or measured
GFR using exogenous markers should be considered
(Table 2).22
DRUG DOSING CONSIDERATIONS FOR PATIENTS WITH CKD
Despite numerous published guidelines46–51 regarding drug
dosing for patients with reduced kidney function, there is
insufficient evidence to guide decisions on many commonly
used drugs. Indeed, occasionally recommendations derived
from postmarketing studies are in conflict with the informa-
tion in the official FDA or EMA product labeling and in
recommendations found in frequently utilized reference
sources. Before 1998, there were no official guidances
regarding the explicit criteria for characterization of the
relationship between drug PK and PD and kidney function.
The FDA industry guidance issued in May 1998,52 and the
EMA guidance of 2004,53 provided frameworks to help
companies decide when they should conduct such a study
and proposed explicit recommendations for study design,
data analysis, and interpretation of the study results in
product labeling.
PK and PD data
The primary literature is replete with studies of the effect of
CKD on the PK or PD of many of the most commonly
prescribed medications. There are however many challenges
associated with the application of these data in clinical
practice. The volume of distribution (VD) of many drugs is
Table 2 | Assessment of kidney function
Recommendations
Clinical practice 1. Glomerular filtration rate (GFR) should be the standard measure to evaluate kidney function for staging of CKD and
drug dosing purposes
2. Clinicians should use the most accurate method/tool to assess kidney function for the individual patient (i.e., eCLcr or
eGFR or mGFR)
3. Timed clearances of creatinine and urea may be particularly of value for patients with AKI
4. Metrics to determine the most accurate eGFR methodology include rigor of development process, comparison to gold
standard, and measures of bias, precision, and accuracy in multiple patient populations
5. Clinical laboratories should report eGFR in ml/min as well as ml/min per 1.73m2
Research 1. Studies are needed to determine the best method to individualize drug dosing to body size
2. In AKI, studies are needed to establish the role of new biomarkers in detecting early changes in GFR
Regulatory 1. GFR should be measured directly with an inert tracer (e.g., inulin, iohexol, iothalamate, etc.) to determine the relationship
between pharmacokinetic or pharmacodynamic alterations due to kidney dysfunction and GFR
2. If GFR is measured directly during pharmacokinetic and pharmacodynamic studies, then whatever method of eGFR that
is used clinically for drug dosing will always be referenced to a measured GFR
3. Drug labels should refer to measured or estimated GFR without specifying the methodology to be used for drug dosing
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; eCLcr, estimated creatinine clearance; eGFR, estimated glomerular filtration rate; mGFR, measured
glomerular filtration rate.
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increased in patients with moderate to severe CKD as well as
in those with preexisting CKD who develop AKI.2,54,55 This
increase in VD may be the result of decreased protein
binding, increased tissue binding, or alterations in body
composition (for example, fluid overload). There is now
good preclinical and emerging clinical evidence that CKD
may lead to alterations in nonrenal clearance of many
medications as the result of alterations in the activities of
uptake and efflux transporters as well as cytochrome
P450 (CYP enzymes) in the liver and other organs.56–58
Prediction of the effect of impaired kidney function
on the metabolism of a particular drug is however difficult
and there is currently no quantitative strategy to predict
changes for one drug based on data from another in the
same class.
Patients with CKD may experience accumulation of
metabolite(s) as well as the parent compound. This may
result in unforeseen consequences as the metabolites of some
drugs have significant pharmacologic activity. However, the
PK and PD of metabolites are not often fully elucidated
during clinical trials. Thus, the patient with CKD is being
exposed to a new pharmacologic entity as the sum of the
serum concentrations of the metabolite(s) and the parent
compound are markedly different than those reported in
patients with normal renal function.
The metabolite may have pharmacologic activity similar
to that of the parent drug and thus contribute significantly to
clinical response. Alternatively, the metabolite may have
qualitatively dissimilar pharmacologic action; for example,
normeperidine has central nervous system stimulatory
activity that has caused seizures in some with CKD and
AKI.59 Because of the multiplicity of potential interactions of
compounds that are primarily metabolized, the practical
consequences of metabolite accumulation are difficult to
predict.
Goals of therapy
The desired dosage regimen adjustment goals for some agents
are drug class specific. The desired goal may be: the
maintenance of a similar peak, trough, or average steady-
state drug concentration or for antibiotics an optimized
PD measure such as the time above the minimum inhibitory
concentration or the ratio of the drug area under
the concentration time curve (AUC) to the minimum
inhibitory concentration.60 When there is a significant
relationship between drug concentration and clinical
response61 (for example, aminoglycosides) or toxicity62 (for
example, phenytoin), then attainment of the specific target
values becomes critical. If, however, no specific PK or PD
target values have been reported, then a regimen goal of
attaining similar average steady-state concentrations may be
appropriate.
Drug dosage regimen individualization
Most dosage adjustment guidelines have proposed the use of
a fixed dose or interval for patients with broad ranges of
kidney function that are different from those that are the
foundation of the current CKD classification system.54,55,63–65
Indeed, in the FDA guidance, normal kidney function has
often been ascribed to anyone who has a CLcr 480–90 ml/min.
In addition, mild, moderate, and severe impairments in
kidney function are often defined differently among the PK
studies, and each of these categories often encompasses a
broad range of kidney function. The drug dosage adjustment
recommendations that use broad ranges of kidney function
may not be optimal for all patients whose kidney function
lies within the range especially for agents that have a narrow
therapeutic index.
Developing drug dosage adjustment recommendations for
the CKD patient is often predicated on the attainment of the
desired exposure goal (see above) at steady state that will
surely be delayed because of the reduced clearance and
prolonged half-life of the drug. In order to achieve the
desired goal in a timely fashion, a stepwise approach that
includes multiple considerations (see Table 3) for each
individual drug has been proposed.49 Indeed, in some
patients, the clinical circumstance may suggest that a lower
or higher dose be used than is indicated by the drug dosing
guidelines. The following parameters may help guide
individual therapy.
Loading dose. Most published guidelines do not recom-
mend a loading dose, despite the well-documented evidence
of altered VD of several drugs in CKD patients. Loading doses
may be required if a drug has a long half-life and there is a
need to rapidly achieve the desired steady-state concentra-
tions. Furthermore, if the VD of a drug is significantly
increased in CKD patients, a loading dose will likely be
needed even if one was not routinely recommended for those
with normal renal function. If the relationship between VD
and CLcr has been characterized, then the VD should be
estimated from that relationship. If that is not the case, a
modified loading dose can be calculated if one knows the
degree of change in the VD.
Patient’s loading dose ¼ Usual loading dose½ðPatient’s VDÞ=ðNormal VDÞ
ð1Þ
Maintenance dose. The predicted VD may be used with
the predicted elimination rate constant (k) or total body
clearance (CLT) of the drug to yield an adjusted dosing
interval and maintenance dose when one desires to achieve a
specific target serum concentration.5,6,58 If the goal of a
maintenance dosing regimen is however to attain a similar
steady-state drug concentration time profile, that is, AUC, as
would occur if the patient had normal kidney function, a
simple proportional approach can be utilized. In general,
prolonging the dosing interval but maintaining the same
dose will result in the achievement of similar peak and trough
concentrations as well as AUC and thus may be preferred.
Measurement of therapeutic drug levels. Measuring drug
concentrations is one way to optimize therapeutic regimens
and account for changes between and within individuals.
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Therapeutic drug monitoring requires availability of rapid,
specific, and reliable assays and known correlations of drug
concentration to therapeutic and adverse outcomes. In
addition, hypoalbuminemia may influence interpretation of
drug concentrations as the total drug concentration may be
reduced even when the active unbound drug concentration is
not. Unbound drug concentrations are often not clinically
available, and therefore clinicians must empirically consider
the impact of hypoalbuminemia in their interpretation of
measured total drug concentrations (Table 4).55,66,67
DRUG DOSAGE CONSIDERATIONS FOR PATIENTS WITH AKI
Critically ill patients frequently develop AKI, multiorgan
dysfunction syndrome (MODS), or multisystem organ failure
(MSOF).3,68–70 Although most cases of MSOF/MODS occur
secondary to shock, sepsis, and severe trauma, a multiplicity
of other risk factors have been identified. Over 90% of
patients who develop MSOF/MODS have early respiratory
dysfunction. Cardiac dysfunction is often observed shortly
thereafter, followed by hepatic dysfunction within 4–6 days
and AKI in 5–7 days. Unfortunately, there are large gaps in
knowledge of drug metabolism and disposition in patients
with MSOF/MODS as well as AKI, and thus patients may be
at significant risk for underdosing as well as overdosing.
PK and PD data
The application of PK principles involving changes in
absorption, distribution, metabolism, and excretion is the
first step to optimizing drug therapies for patients with AKI,
MSOF, or MODS.71,72 Critically ill patients typically have
minimal oral intake of food and liquids and rely upon
intravenous fluids for fluid maintenance and nutrition. In
addition, H2-antagonists and proton pump inhibitors are
used for stress ulcer prophylaxis and they significantly
increase the gut pH. Any orally administered drug needing
an acidic environment for dissolution may thus not be readily
absorbed. Other absorption-altering conditions such as slow
gastrointestinal motility, prolonged intestinal transit times,
bacterial colonization, and necrotizing enterocolitis (seen in
neonates) have also been noted in these patients. Thus,
intravenous administration of drugs may need to be
considered to assure appropriate absorption.
Drug distribution is one of the most important, yet the
most complicated, physiologic variable to quantify for
patients with AKI, MSOF, or MODS. There is a fine balance
between detrimental fluid overload and adequate hydration
to preserve kidney perfusion. Numerous studies in both adult
and pediatric patients have concluded that critically ill
patients should early on be managed in a slightly negative
fluid balance after initial adequate fluid resuscitation.68,73–75
However, in patients prone to low blood pressure, this may
not be prudent. Careful and frequent reassessment of volume
status is mandatory in this patient situation.
Multiple animal57,76–78 and a few human studies57,79–82
have demonstrated a reduction in the transcription and/or
metabolic activity of hepatic and intestinal CYP450 in CKD
patients. The impact of AKI, MSOF, and MODS on drug
metabolism is delayed in onset or minimal in the majority of
studies,83–85 whereas nine studies did not demonstrate any
impact on hepatic metabolic activity.86–94 The remaining four
studies revealed either an increase or a decrease in hepatic
metabolic activity.95–98 Definitive conclusions on the PK of
metabolized medications in AKI remain hampered by the
clinical complexity and potential confounders in the critically
ill patients. Hypoxia, decreased protein synthesis, competitive
inhibition from concomitant medications, and decreased
hepatic perfusion could also be explanations for the reduced
clearance.
Patient assessment
Hyperfiltration and massive overhydration are often evident
early in the course of MSOF/MODS, especially in those with
burns or trauma, and can lead to the use of inappropriately
low doses of medication, treatment failure, and even death.99
Hypofiltration and GFR may be especially challenging to
quantify in those with rapidly changing function.8,51 Finally,
estimation or measurement of GFR may not provide an
accurate measure of the contribution of the kidney to the
excretion of all drugs, especially those that are extensively
secreted and/or metabolized in the kidney or other
organs.100,101 Several new quantitative techniques and
assessment protocols have been developed and utilized in
patients with ‘stable’ CKD, liver disease, and some other
conditions.102–104 The potential benefits of these methods
Table 3 | Stepwise approach to adjust drug dosage regimens for patients with CKD and AKI
Step 1 Obtain history and relevant demographic/clinical
information
Assess demographic information, past medical history including history of renal
disease, and current clinical and laboratory information, including DNA
polymorphisms to ascertain drug therapy needs
Step 2 Estimate GFR Use most appropriate tool to assess eGFR or CLcr for the patient based on age, body
size, ethnicity, and concomitant disease states
Step 3 Review current medications Identify drugs for which individualization of the treatment regimen will be necessary
Step 4 Calculate individualized treatment regimen Determine treatment goals (see text); calculate dosage regimen based on
pharmacokinetic characteristics of the drug and the patient’s volume status and
eGFR or CLcr
Step 5 Monitor Monitor parameters of drug response and toxicity; monitor drug levels if available/
applicable
Step 6 Revise regimen Adjust regimen based on drug response or change in patient status (including renal
function) as warranted
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CLcr, creatinine clearance; eGFR, estimated GFR; GFR, glomerular filtration rate.
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include an improvement in dosage individualization and
identification of the mechanisms responsible for nephrotoxic
injury. Although both methods have been validated, there has
been no subsequent published data regarding their applica-
tion in patients with CKD, AKI, or MSOF/MODS.
Assessment of kidney function in patients with AKI or
MSOF/MODS is challenging.105–107 Any endogenous filtra-
tion marker, such as creatinine, needs to be measured at
steady state before it can provide a reliable estimate of GFR.
Hence, no estimating equations can provide an accurate
estimate of GFR in AKI. The rate of change of SCr or eGFR
may provide some insight but this cannot be used as a
quantifiable measure, and such values cannot be applied to
individual patient situations as multiple events are typically
happening concurrently. Another strategy to estimate GFR in
AKI is to measure creatinine clearance with incorporation of
the mean of the beginning and ending Scr value as an estimate
of GFR. Shorter time periods than 24 h may be appropriate in
patients with rapidly changing levels of kidney function. For
patients with MSOF/MODS without AKI, Scr and all related
estimating equations are likely to overestimate the GFR or
creatinine clearance because of the influence of non-GFR
determinants in these clinical scenarios.
There is a paucity of dosing algorithms to guide
pharmacotherapy, derived from investigations of the PK/PD
of medications, in patients with AKI or MSOF/
MODS.64,72,108 Indeed, most of the critical care literature
and almost all FDA or EMEA product labeling contains drug
dosage recommendations that were derived from observa-
tions in patients with CKD or those receiving RRT. The
limited data from these populations that are available have
predominantly been developed by clinicians who have gained
experience with a given drug after it has been approved for
marketing, and rarely, if ever, is this information incorpo-
rated into official product labeling. Thus, it is challenging for
clinicians to individualize therapy when the available PK/PD
information is so scant. It is near impossible to provide the
best dosage regimen for AKI or MSOF/MODS patients
Table 4 | Drug dosing considerations for patients with CKD
Recommendations
Clinical practice 1. A single tool to evaluate kidney function for determination of CKD and drug dosing purposes would enable delivery of
high-quality care
2. It should be recognized that drug dosing recommendations developed in the era of high serum creatinine variability will be
applied differently than intended in the original pharmacokinetic study
3. Clinicians should use the most appropriate tool to assess kidney function for individual patient (i.e., measured vs. estimated)
4. Metrics to determine most accurate eGFR include rigor of development process, comparison to gold standard, and
measures of bias, precision, and accuracy
5. Clinical laboratories should also report eGFR in ml/min
6. Drug dosages should be adjusted according to FDA- or EMA-approved product labeling
7. When there is no information in the product label, peer-reviewed literature recommendations should be used to guide
drug dosage regimen adjustments
8. Obese CKD and AKI patients and those with large variations in serum protein levels should have their drug dosage
individualized based on the best available evidence
Research 1. Rigorously conducted PK/PD studies are needed to evaluate the impact of CKD on all drugs. The analysis of these studies
should generate dosage regimen recommendations based on continuous relationship between GFR and clearance as well
as VD when evident
2. Categorical dosage recommendations should be based on pharmacokinetic and exposure response, not predetermined
categories of kidney function
3. Evaluate the relationship between steady-state drug and metabolite exposure when appropriate on drug safety and
efficacy in patients with CKD enrolled in phase II and III and/or postmarketing studies
4. Evaluate the impact of interactions of all drugs commonly used in CKD patients (e.g., phosphate binders, PPI)
5. Design and test methods to translate knowledge of PK/PD and drug interactions into clinical practice (e.g., clinical decision
support systems)
6. Develop database of patients with CKD with PK/PD data and outcomes (safety/efficacy) data
7. Examine differences in dosing efficacy and safety related to the use of various kidney function indices
Regulatory 1. Drug labeling should state the strength of evidence for dosing modifications for CKD patients
2. Pharmacokinetic studies in healthy normal volunteers and CKD stage 1–5 patients should be conducted for all renally
eliminated drugs
3. Reduced PK studies should be performed for all drugs. Study population should include patients on HD and the study
should be initiated on a non-HD day
4. Measured GFR should be the standard for renal function and the relationship between PK/PD parameters and multiple
estimating equations should be assessed
5. Pharmacokinetic data from CKD patients provided to FDA should be publicly available and accessible in user-friendly
format
6. Drug labels should indicate the dosage recommendations based on measured GFR rather than a specific estimation
equation
7. Further evaluations of the safety and efficacy of the proposed dosage regimens should be assessed in postmarketing
studies in patient populations not sufficiently represented in premarketing studies
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated GFR; EMA, European Medicines Agency; FDA, US Food and Drug Administration; GFR,
glomerular filtration rate; HD, hemodialysis; PD, pharmacodynamics; PK, pharmacokinetics; PPI, proton pump inhibitors; VD, volume of distribution.
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because of their fluctuating kidney function, volume status,
and potentially metabolic activity.
Drug dosing approaches
The principles of drug dosage regimen modification
previously described for use in CKD patients are the
foundation for those with AKI or MSOF/MODS.
Loading dose. As the VD of many drugs, especially
hydrophilic antibiotics, including b-lactams, cephalosporins,
and penems, are significantly increased in the presence of
AKI, the administration of aggressive loading doses (25–50%
greater than normal) are highly recommended.
Maintenance dose. Clinical judgment is paramount and
forecasting the degree and rate of change in kidney function
and fluid volume status is fraught with uncertainty. Because
of the preservation of nonrenal clearance for some agents
such as vancomycin, imipenem, and ceftizoxime, as well as
the tendency to attain a positive fluid balance in the early
stages of AKI, the dosing regimen for many drugs, especially
antimicrobial agents, should be initiated at normal or near-
normal dosage regimens.
Therapeutic drug monitoring. Prospective measurement of
serum drug concentrations and the subsequent use of sound
PK/PD therapeutic drug monitoring approaches should be
used whenever possible, especially for drugs with a narrow
therapeutic range. When this is not a possibility because of
the unavailability of rapid specific analytical methods for the
determination of serum drug concentrations, the develop-
ment of excessive pharmacologic effect or toxicity may be the
primary indicator of a need for dosage adjustment. Finally,
there are currently very limited data to guide drug dosing for
AKI or MSOF/MODS patients receiving one of the multiple
variants of RRT (Table 5).64,72,108
DRUG DOSING CONSIDERATIONS FOR HD PATIENTS
The optimization of pharmacotherapy for patients receiving
intermittent HD is critically dependent on the availability of
reliable information from well-designed PK studies. The
artificial kidney is an ideal eliminating ‘organ’ because, in
contrast to renal or hepatic routes of drug elimination, blood
flow to the dialyzer, drug concentrations in blood entering
and leaving the dialyzer, and recovery of eliminated drug can
all be measured.109
PK and PD data
Although many hemodialyzers have been introduced in the
past 10 years, and more than 100 different ones were available
in the United States in 2011, the effect of HD on the
disposition of a drug is rarely evaluated more than once.
Thus, most of the literature, especially for older medications,
probably represents an underestimation of the impact of HD
on its disposition.110
The impact of HD on a patient’s drug therapy is
dependent on several factors, including the drug character-
istics, the dialysis prescription, and the clinical situation for
which dialysis is performed. Drug-related factors include the
molecular weight or size, degree of protein binding, and
distribution volume.2,62 The vast majority of dialysis filters in
use until the mid 1990s were composed of cellulose, cellulose
acetate, or regenerated cellulose (cuprophane); and they
were generally impermeable to drugs with molecular
weights 41000 Daltons.109 The HD procedure prescription
can dramatically affect the dialysis clearance of a medica-
tion.111 The primary factors that vary between patients are
the composition of the dialysis filter, the filter surface area,
the blood, dialysate and ultrafiltration rates, and whether or
not the dialysis unit reuses the dialysis filter. Dialysis
membranes in the twenty-first century are predominantly
composed of semisynthetic or synthetic materials
(for example, polysulfone, polymethylmethacrylate, or
polyacrylonitrile). High-flux dialysis membranes have the
larger pore sizes and this allows the passage of most solutes,
including drugs that have a molecular weight of p20,000
Daltons.109,110
The impact of HD is not strictly limited to dialysis
clearance. There is evidence that some drugs adhere to the
dialyzer membrane, and recent findings suggest that the
nonrenal clearance (metabolism) of some agents is altered by
HD. A single 4-h session of HD increased the nonrenal
clearance of erythromycin in patients with end-stage renal
disease by 27% as soon as 2 h after HD.112 This was
presumably secondary to the removal of uremic solutes that
accumulate during the interdialytic period and inhibited
CYP450 3A4 and drug transporters. A subsequent study of
midazolam in subjects with end-stage renal disease impli-
cated transporters (human organic anion-transporting poly-
peptide and/or intestinal P-glycoprotein) as the likely drug
disposition bottleneck in uremia rather than CYP3A4.56
Should CLNR actually increase during HD, this would lead to
an overestimation of CLD.
Assessment of the impact of HD
The most common method for assessing the effect of HD is
to calculate the dialyzer clearance (CLD) of the drug; CLD
b
from blood can be calculated as CLD
b ¼Qb[(AbVb)/Ab],
where Qb is blood flow through the dialyzer, Ab is the
concentration of drug in blood going into the dialyzer, and
Vb is the blood concentration of drug leaving the dialy-
zer.113–117 This equation, which has been termed the ‘A-V
difference method,’ is only valid if the drug concentrations
are measured in whole blood and if the drug rapidly and
completely distributes into red blood cells. Because drug
concentrations are generally determined in plasma, the
previous equation is usually modified to CLD
p ¼Qp
[(ApVp)/Ap] where p represents plasma and Qp is plasma
flow, which equals Qb (1hematocrit). This equation tends
to underestimate HD clearance for drugs that readily
partition into and out of erythrocytes. In addition, venous
plasma concentrations may be artificially high if extensive
ultrafiltration is performed and thus CLD
p will be low if
plasma water is removed from the blood at a faster rate
than drug.
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Because of the above limitations, the recovery clearance
approach remains the benchmark for the determination of
dialyzer clearance and it can be calculated as:2,115,116
CLD
r ¼R/AUC0t where R is the total amount of drug
recovered unchanged in the dialysate and AUC0t is the
area under the predialyzer plasma concentration–time
curve during the period of time that the dialysate was
collected. To determine the AUC0t, a minimum of three
to four plasma concentrations should be obtained during
dialysis.
The HD clearance values reported in the literature may
vary significantly depending on which of these methods were
used to calculate CLD. The principal reason for this is that for
most medications we do not know the degree and rapidity
with which the drug crosses the red blood cell mem-
brane.2,110,113 Because the CLD
r method incorporates no
Table 5 | Drug dosing considerations for patients with AKI
Recommendations
Clinical practice 1. The KDIGO AKI, AKIN, RIFLE, or pRIFLE criteria should be prospectively utilized to optimize the identification of patients at
highest risk of developing AKI
2. High-risk medications, those with known nephrotoxicity, or other potential toxicities associated with supratherapeutic serum
concentrations should be identified proactively, for example, computerized order entry, so that the prescribing clinician can
closely monitor patient response
3. The volume of distribution of several medications is dramatically increased in the presence of AKI and thus larger loading
doses may need to be administered to avoid subtherapeutic responses due to the achievement of lower than desired serum
concentrations
4. When possible, therapeutic drug monitoring should be utilized for those medications where serum drug concentrations can
be obtained in a clinically relevant time frame
5. Trends in renal function indices such as serum creatinine and urine output along with volume status should be utilized to
guide drug dosing when rapidly measurable indices are unavailable
6. For those medications where therapeutic drug monitoring is not possible, close monitoring of drug PD may prove to be a
useful surrogate
7. Evaluation of risk for drug–drug and drug–nutrient interactions should be facilitated by incorporating validated electronic
drug interaction tools into EMRs
8. A patient-centered team approach that includes an ICU pharmacist is recommended to prevent medication-related problems
and enhance safe and effective medication use
9. EMRs should maintain records for discontinued medications for up to 7 days to make it possible to assess potential residual
effects on the patient’s current condition
Research 1. Evaluate the sensitivity and reliability of biomarkers to predict risk for the development of AKI and quantify the degree of
injury
2. Formulation and validation of rapid and reliable direct measurement methods or estimating formulas for kidney and liver
function are definitively needed to prospectively ascertain the trajectory of the patient’s kidney or liver function
3. Generate guidelines for the frequency of prospective monitoring of kidney function and drug dosing adjustments in patients
with AKI
4. If estimating equations are to be used, these should be validated against measured values determined via state-of-the-art
standard techniques for assessing kidney function
5. Clinical studies of nonrenal clearance of the most commonly used metabolized medications and the most important hepatic
enzymes, CYP2D6, 2C9, 2C19, and 3A4 in AKI are imperative given the emerging evidence that the activity of these enzymes
are altered in the presence of CKD
6. Specific and rapid drug assays (LC-MS/MS) for high-risk medications should be developed and widely available so that
pharmacokinetic studies of medications used in AKI patients receiving and not receiving various RRTs can be conducted
7. Development and validation of ‘standardized ICU drug assay panels’ (e.g., multiple antibiotics) to facilitate therapeutic drug
monitoring to optimize patient outcomes. Validation should include assessment of assay interference with commonly used
medications in AKI patients
8. Encourage further development of electronic tools/decision-making software to guide drug dosage individualization and
detect, ascertain causality, and prevent drug interactions
9. Create open-access databases, based on FDA Medwatch system, to collect information regarding potential drug adverse
events and drug interactions in AKI patients
10. Develop a longitudinal medication history to aid in the identification of residual effects of drugs on the pharmacokinetics,
dynamics as well as the patient’s sensitivity to the development of adverse events
11. Create a mechanism to enroll AKI patients upon ICU admission into PK and PD studies across the spectrum of AKI
Regulatory 1. PK and PD studies of all medications in patients with stage 3–5 AKI should be conducted so that reliable drug dosing
recommendations can be developed
2. The innovator of a new drug likely to be used in the ICU setting should during the drug development process establish
methodologies for the analysis of drug concentrations in the clinical setting so that the value of TDM in AKI patients can be
assessed
3. Drug labeling should state the level of evidence for the safe and effective use in AKI
4. Mandate changes in drug labeling to reflect measurement techniques used for establishing the patient’s organ clearance that
are the foundation of drug dosing individualization
5. Mandate postmarketing studies to validate drug clearance relationships with ‘standard’ organ function assessments
performed in stable patients with chronic disease are relevant in the setting of MODS
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; CKD, chronic kidney disease; EMRs, electronic medical records; FDA, US Food and Drug
Administration; ICU, intensive care unit; KDIGO, Kidney Disease: Improving Global Outcomes; LC-MS/MS, liquid chromatography/mass spectrometry; MODS, multiorgan
dysfunction syndrome; PD, pharmacodynamics; PK, pharmacokinetics; RRT, renal replacement therapy; RIFLE, risk, injury, failure, loss, end-stage kidney disease; pRIFLE,
pediatric risk, injury, failure, loss, end-stage kidney disease; TDM, therapeutic drug monitoring.
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assumption of the degree of red blood cell permeability, it can
be reliably used as the benchmark value. The primary
limitation of this calculation is that the concentrations of the
drug in the dialysate may be below the sensitivity limits of the
assay. A continuing clinical problem is that PK results
obtained with one dialyzer are generally not representative of
the performance of another dialyzer.2,110 Thus, there is a
critical need to characterize CLD estimates made with one
dialyzer in a way that results can be readily extrapolated to a
different dialyzer.118 Therapeutic drug monitoring, including
measurement of the dialyzer clearance, should be utilized for
drugs with a narrow therapeutic range, for example,
aminoglycosides and vancomycin. Finally, drug dosage
recommendations derived from studies conducted before
2000 likely represent an underestimate of the impact of HD
and dosages may need to be empirically increased by 25–50%
(Table 6).
DRUG DOSING CONSIDERATIONS FOR PATIENTS
RECEIVING CRRT
Continuous renal replacement therapy (CRRT) is commonly
used to manage hemodynamically unstable AKI patients.
Several modes of therapy (convective, diffusive, or both), a
variety of filter materials, and different effluent flow rates are
used,111,119 all of which can influence drug removal.
PK and PD data
Despite the large variability in CRRT techniques, a review of
published clearance studies found that o90% of studies
specified the prescribed CRRT dose and only 58% of
continuous venovenous hemofiltration studies specified
whether pre- or post-dilution mode was used.120 Two basic
PK values necessary for interpretation of study results, VD
and CL, were specified in only 79% and 81% of studies,
respectively. None of the reviewed studies contained the ‘ideal
data set’ formulated by the authors.
Hybrid RRTs that utilize higher dialysate flow rates than
those used in CRRT, and shorter treatment periods (6–12 h in
duration), are frequently prescribed as well. Hybrid therapies
include slow low-efficiency dialysis (SLED), extended
daily dialysis, continuous SLED, slow low-efficiency daily
dialysis (SLEDD), and slow low-efficiency daily hemodiafil-
tration (SLEDD-f). Finding relevant literature for application
to a given clinical situation is thus challenging and PK
interpretation difficult.121–125 The intermittent nature of
most hybrid RRTs can further complicate drug dosing, as
higher doses may be needed during the therapy, whereas
lower doses may be adequate during therapy downtime.
To date, hybrid RRT PK data have been published for only
12 drugs.126–139
Assessment of the impact of CRRT and hybrid RRT
CRRT parameters substantially influence drug clearance. The
mode of therapy (diffusion, convection, or both) can be
influential, as both therapy modes can remove small solutes,
but convective therapies are superior at removing larger
solutes.140,141 Drug clearance is affected by where replace-
ment fluids are given, because this influences the drug
concentration within the filter. Mathematical calculations
can account for this,142–144 but published studies do not
always specify this information.120 Filter composition can
also influence drug removal.145,146 Some degree of drug
Table 6 | Drug dosing considerations—hemodialysis
Recommendations
Clinical practice 1. The dose should be given after dialysis (Dhd) to ensure active drug levels until next dosing. Consider a supplementary
(Dsup) dose in addition to the dose adjusted to kidney failure (Dfail) after dialysis to replace the fraction removed by dialysis (Fr)
Dhd=Dfail+Dsup where Dsup=Fr (DstartDfail)
2. The Dsup derived from studies of low-flux nonsynthetic membranes should empirically be increased by at least 50% when
patients are dialyzed with high-flux synthetic dialyzers
3. Extended dialysis regimens with high diffusive membranes have been associated with extensive drug clearances and thus the
Dsup may need to be increased
Research 1. Develop accurate and reproducible methods to quantitate dialysate and ultrafiltration flow rates and collect representative
aliquots because the clinical utility of pharmacokinetic studies in HD patients is critically dependent on the accuracy of these
procedural variables
2. Develop methodologies to quantitate the degree of drug adsorption to the dialyzer membrane and associated elements in the
extracorporeal circuit as this route of drug removal impacts the overall dialyzer clearance
3. The drug should be administered intravenously at a sufficient interval before HD is instituted so that predialysis distribution
and elimination PK can be fully characterized
4. The dialyzer model and all the components of the dialysis prescription should be reported for each individual studied. The
dialysis prescription should be standardized as much as clinically feasible to enhance the generalizability of the data
5. The time course and the extent of the postdialysis rebound in drug serum concentrations should be assessed and the resultant
data incorporated into the drug dosage regimen recommendation
Regulatory 1. FDA and EMA should mandate that the PK/PD including determination of the HD clearance be evaluated for all drugs that will
likely be used in ESRD patients
2. In vitro and in vivo dialysis studies should use a standard array of model substrates such as creatinine, vitamin B12 or
vancomycin, and b2-microglobulin. This will facilitate extrapolation of the results with one hemodialyzer to another as it is
impractical to mandate studies be done with all commercially available dialyzers
Abbreviations: EMA, European Medicines Agency; ESRD, end-stage renal disease; FDA, US Food and Drug Administration; HD, hemodialysis; PD, pharmacodynamics;
PK, pharmacokinetics.
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adsorption occurs with many CRRT membranes (particularly
sulfonated polyacrylonitrile and polymethylmethacrylate),
although it is difficult to quantify adsorption in both
in vitro and in vivo studies.95,147,148 Dialysis dose is one of
the most influential factors, with increased dialysate/ultra-
filtration/effluent flow rates resulting in greater drug
removal.146,147
Drug dosing approaches
The clinical desire to deliver higher RRT doses as well as the
improvement of RRT machines and filters has rendered old
dosing guidelines for drugs, especially antibiotics, ineffectual
and potentially dangerous.55,64 PK studies conducted in
critically ill patients receiving CRRT or hybrid RRT are rare
and dosing guidelines for these therapies are not often
presented in a drug’s product labeling. There are several
published dosing recommendation guidances that are widely
used.62,64,108,149,150 These recommendations have not been
prospectively tested to see if their application increases the
attainment of therapeutic target serum concentrations or,
more importantly, patient outcomes. The limitations of those
calculations are illustrated by the fact that two different
recommended doses for some antibiotics differ by up to an
order of magnitude (Table 7).
DRUG DOSING CONSIDERATIONS FOR PATIENTS RECEIVING
PERITONEAL DIALYSIS
Peritoneal dialysis as practiced in 2011 is very unlikely to
enhance total body clearance of any drug by more than 10 ml/
min, as most typical peritoneal dialysis prescriptions are
designed to achieve a urea clearance ofB10 ml/min. As most
drugs are larger than urea, their clearance is even less; thus,
drug clearance will likely be in the range of 5 to 7.5 ml/min.
Many studies performed in the 1970s and 1980s showed that
drug clearances by peritoneal dialysis were in this range, and
thus one can conclude that peritoneal dialysis does not
enhance drug removal to a degree that will require a dosage
regimen modification.151–154 Therefore, drug therapy recom-
mendations for those with CLcr or eGFR o15 ml/min are
likely clinically useful.
PK and PD data
In patients with established peritoneal dialysis, the access to
the peritoneal cavity provides an opportunity to deliver drugs
Table 7 | Drug dosing considerations for AKI patients receiving CRRT/EDD
Recommendations
Clinical practice 1. ESRD dosing recommendations should be used only as an initial guide for the initiation of therapy in an AKI patient receiving
CRRT when no other information is available
2. The existing maintenance dosing recommendations for ESRD patients receiving HD often result in the achievement of
subtherapeutic concentrations and treatment failures for patients with severe AKI requiring RRT
3. The most effective dosing optimization strategy is to use therapeutic drug monitoring for drugs like aminoglycosides and
vancomycin to achieve the desired therapeutic goals. However, very few drugs have clinically useful (quick turnaround time,
FDA/EMA approved) assays available
4. When CRRT or EDD clearance data are available, the current literature recommendations should be the logical starting dose for
therapy. Different treatment intensities for CRRT or EDD result in marked variability in drug removal and thus this literature may
not be generalizable across the multiple CRRT and EDD prescriptions that are used in practice
5. Another alternative is to calculate the ‘total creatinine clearance’ (CLcr) based on the addition of the patient’s residual renal
clearance and expected extracorporeal clearance. This value can then be used to estimate a maintenance dosing regimen
based on medication dosing guidelines specified for that resultant total CLcr range. Using this method, most drugs will fall in
the CLcr 25–50ml/min range
6. A fourth method starts with the dose and dosing interval for a patient with a GFRo10ml/min (anuric dose), and makes dosage
adaptations based on the drug fraction expected to be removed by extracorporeal therapy (FrEC)
i. Maintenance dose=anuric dose/[1FrEC]
ii. Dosing interval=anuric dosing interval  [1FrEC]
7. A fifth method starts with a normal dose (Dn) and reduces dose based on normal clearance (Clnorm), non-renal clearance
(Clnonrenal), effluent rate (Qeff), and sieving coefficient (SC)
b. Dose =Dosen [Clnonrenal+(Qeff SC)]/Clnorm
8. CRRT and EDD education should be an integral part of critical care and nephrology fellowship training programs
Research 1. CRRT or EDD clearance data derived from in vitro studies or those conducted in ESRD patients are needed to guide clinical
studies in AKI patients
2. Studies should be conducted in AKI patients to characterize the influence of CRRTs because the PK parameters observed in
ESRD patients are not generalizable to ICU patients
Regulatory 1. FDA and EMA should mandate PK/PD studies at a given, predefined CRRT or EDD intensity level during the preapproval process
or in phase IV studies
2. FDA and EMA should make PK/PD studies a mandatory requirement for antimicrobials and renally excreted drugs that are likely
to be extensively used in the ICU setting
3. Available and future PK/PD data in this patient population should be compiled in a publicly accessible data repository
4. The effect of other extracorporeal techniques should be investigated in terms of their ability to remove/adsorb drugs
5. The results of PK/PD studies conducted in patients receiving CRRT/EDD and dosing guidelines for these therapies should be
presented in a drug’s package insert
Abbreviations: AKI, acute kidney injury; CRRT, continuous renal replacement therapy; CVVH, continuous venovenous hemofiltration; EDD, extended daily dialysis; EMA,
European Medicines Agency; ESRD, end-stage renal disease; FDA, US Food and Drug Administration; GFR, glomerular filtration rate; HD, hemodialysis; ICU, intensive care unit;
PD, pharmacodynamics; PK, pharmacokinetics; RRT, renal replacement therapy.
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both locally and systemically. The degree and rate of drug
transport across the peritoneum depends on the dialysate
volume in which the drug is diluted, the dialysate to plasma
concentration gradient, the molecular size and electrochemi-
cal properties of the drug, the exposure time, and the
peritoneal perfusion rate.155 Intraperitoneal drug adminis-
tration is well accepted for the treatment of peritoneal
dialysis-associated peritonitis and other infections.156,157
Intraperitoneal therapy appears attractive but has several
potential technical pitfalls: solubility and stability of the
compounds in peritoneal dialysis fluid,158,159 and co-admin-
istration of more than one compound can lead to chemical
interactions and changes in solubility. Administration inter-
vals depend on the half-life of the drug, which is mainly
determined by residual renal and extrarenal metabolic
clearance. Long-standing experience with intermittent anti-
biotic administration exists for the glycopeptides vancomycin
and teicoplanin, which can be administered at 5- to 7-day
intervals, as well as for aminoglycosides and cephalosporins,
which are suitable for once-daily dosing.156,160,161
Drug dosing approaches
Although the concept of intermittent antibiotic administra-
tion appears intriguing because of its practicality and cost
efficiency, the efficacy and safety of intermittent dosing is
impacted by several factors. Most importantly, the dialysate
flow rate strongly affects the elimination of the drug.161 In
patients treated by automated peritoneal dialysis with
frequent short dialysis cycles, exposure to peritoneal dialysis
fluid with a given antibiotic concentration over several cycles
may result in higher plasma concentrations as compared with
antibiotic loading in a single extended dwell period in
patients on continuous ambulatory peritoneal dialysis.
Conversely, the higher dialysate flow and small molecule
clearance achieved with automated peritoneal dialysis regi-
mens may lead to a greater peritoneal clearance of antibiotic
in the periods between dosing (Table 8).157
CONCLUSIONS AND PERSPECTIVES
The discussion of the large body of evidence by the
conference participants clearly indicates that there have been
significant advances in knowledge of the influence of kidney
function and RRTs on drug disposition during the past 30
years. The clinical practice recommendations were made to
help guide clinicians and will hopefully serve as stimuli for
the establishment of further standards of practice for the
enhancement of patients’ clinical outcomes.
It was also clear that there were significant gaps in
knowledge of the PK and PD of most drugs in AKI and CKD
patients. As such, establishment of a research agenda was a
focus of much of the conference. Furthermore, the evolution
of RRTs mandates the inclusion of a higher level of rigor in
future investigations so that the quality of the data is
improved and its clinical utility enhanced. Indeed, much of
Table 8 | Drug dosing considerations—peritoneal dialysis
Recommendations
Clinical practice 1. As most pharmacokinetic studies establishing peritoneal antibiotic doses have used 4- to 8-h loading periods, it is
recommended to perform antibiotic loading by an extended cycle in both CAPD and APD patients. For intermittent
maintenance dosing, a long nighttime dwell should be used in CAPD and a long daytime dwell in APD patients
2. Intermittent antibiotic dosing has not been unequivocally successful in eradicating bacterial growth, partially questioning the
concept of antibiotic back diffusion into the peritoneal cavity. Transperitoneal drug movement may be less effective in the post
acute phase of peritoneal infection when inflammation-related capillary hyperperfusion subsides
3. Short dwell times in APD patients may prevent accumulation of antibiotic in the peritoneal cavity to concentrations exceeding
the minimal inhibitory concentrations
4. Monitoring of drug blood levels is advocated in patients receiving intraperitoneal antibiotics because they are at increased risk
for under- and over-dosing, that is, those with significant residual renal function and those on intense APD schedules,
respectively. Monitoring of dialysate concentrations may provide even more relevant information
Research 1. CAPD patients are a suitable group for PK and PD studies in end-stage renal disease as they represent a steady-state clinical
condition
2. Peritoneal dialysis drug clearance may need to be characterized for many more drugs than in the past due to the introduction
of high- and continuous-flow peritoneal dialysis variants, which are likely to become available for both acute and chronic
patients in the foreseeable future
3. Although the intraperitoneal route is a well-established administration mode for some agents, especially antibiotics in patients
with peritoneal dialysis-associated peritonitis, several aspects of this dosing approach require further research. These include
assessment of the degree of equivalence of drug absorption across a noninflamed vs. inflamed peritoneum and the
determination of the optimal administration schedule to achieve adequate systemic drug exposure
4. Simulation studies of bidirectional transperitoneal drug transport would be particularly relevant in intermittently treated
patients on automated peritoneal dialysis, in whom alternating phases of rapid nocturnal cycling and daytime rest might result
in complex pharmacokinetic patterns
5. Finally, the efficacy and safety of intermittent and continuous dosing protocols should be studied in clinical trials
Regulatory 1. The limited and continuous drug clearance achieved with many modes of peritoneal dialysis does not warrant a mandate to
conduct PK/PD studies of all new drugs
2. However, as the transperitoneal route is a well-established administration mode mainly for antibiotics and antifungal agents in
patients with peritoneal dialysis-associated peritonitis, it is recommended that PK studies of new agents in these classes be
conducted in the postmarketing period
Abbreviations: APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; PD, pharmacodynamics; PK, pharmacokinetics.
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the data that are currently available are now only of historical
value. The challenge is that there is no obvious source of
funding for such research activities. These questions are not
hypothesis driven, and thus not generally the basis for
investigator-initiated grants. Industry supports much of the
research that goes into the development of new drugs, but
there is no mechanism at present for funding postmarketing
studies in patients with kidney function impairment,
especially those with AKI who are receiving CRRT. Recogni-
tion of funding sources is an important step in addressing
many of these issues.
The regulatory recommendations were considered critical
to the conference process as in many cases the quest to better
understand the drug dosing needs of AKI and CKD patients
is driven by drug-approval agency expectations of the
pharmaceutical and biotechnology industry. The KDIGO
Controversies Conference highlighted the gaps but more
importantly focused on crafting paths to the future that will
stimulate research and improve the global outcomes of
patients with kidney injury and disease.
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